These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 17197522)
1. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Bandello F; Lafuma A; Berdeaux G Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):96-103. PubMed ID: 17197522 [TBL] [Abstract][Full Text] [Related]
2. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Dong LM; Childs AL; Mangione CM; Bass EB; Bressler NM; Hawkins BS; Marsh MJ; Miskala P; Jaffee HA; McCaffrey LA; Am J Ophthalmol; 2004 Jul; 138(1):91-108. PubMed ID: 15234287 [TBL] [Abstract][Full Text] [Related]
3. Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Cahill MT; Banks AD; Stinnett SS; Toth CA Ophthalmology; 2005 Jan; 112(1):152-8. PubMed ID: 15629836 [TBL] [Abstract][Full Text] [Related]
4. Vision-related quality of life in patients suffering from age-related macular degeneration. Berdeaux GH; Nordmann JP; Colin E; Arnould B Am J Ophthalmol; 2005 Feb; 139(2):271-9. PubMed ID: 15733988 [TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Slakter JS; Stur M Surv Ophthalmol; 2005; 50(3):263-73. PubMed ID: 15850815 [TBL] [Abstract][Full Text] [Related]
6. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Fletcher EC; Lade RJ; Adewoyin T; Chong NV Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556 [TBL] [Abstract][Full Text] [Related]
7. Age-related macular degeneration in Onitsha, Nigeria. Nwosu SN Niger J Clin Pract; 2011; 14(3):327-31. PubMed ID: 22037079 [TBL] [Abstract][Full Text] [Related]
8. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737 [TBL] [Abstract][Full Text] [Related]
9. A comparison of macular translocation with patch graft in neovascular age-related macular degeneration. Chen FK; Patel PJ; Uppal GS; Rubin GS; Coffey PJ; Aylward GW; Da Cruz L Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1848-55. PubMed ID: 19060287 [TBL] [Abstract][Full Text] [Related]
10. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Brown MM; Brown GC; Brown HC; Peet J Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724 [TBL] [Abstract][Full Text] [Related]
11. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Shah AR; Del Priore LV Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101 [TBL] [Abstract][Full Text] [Related]
12. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Fletcher DC; Schuchard RA Optom Vis Sci; 2006 Mar; 83(3):178-89. PubMed ID: 16534460 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and causes of visual impairment and blindness in Icelanders aged 50 years and older: the Reykjavik Eye Study. Gunnlaugsdottir E; Arnarsson A; Jonasson F Acta Ophthalmol; 2008 Nov; 86(7):778-85. PubMed ID: 18513265 [TBL] [Abstract][Full Text] [Related]
14. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Abbott EJ; Connor GB; Artes PH; Abadi RV Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1416-23. PubMed ID: 17325191 [TBL] [Abstract][Full Text] [Related]
15. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999. Coleman AL; Yu F Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499 [TBL] [Abstract][Full Text] [Related]
16. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Wong TY; Chakravarthy U; Klein R; Mitchell P; Zlateva G; Buggage R; Fahrbach K; Probst C; Sledge I Ophthalmology; 2008 Jan; 115(1):116-26. PubMed ID: 17675159 [TBL] [Abstract][Full Text] [Related]
17. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Verma L; Das T; Binder S; Heriot WJ; Kirchhof B; Venkatesh P; Krebs I; Stolba U; Jahn C; Feichtinger H; Kellner L; Krugluger H; Pawelka I; Frohner U; Kruger A; Li W; Tewari HK Indian J Ophthalmol; 2000 Dec; 48(4):263-78. PubMed ID: 11340884 [TBL] [Abstract][Full Text] [Related]
18. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Hayashi H; Yamashiro K; Tsujikawa A; Ota M; Otani A; Yoshimura N Am J Ophthalmol; 2009 Jul; 148(1):83-9.e1. PubMed ID: 19327745 [TBL] [Abstract][Full Text] [Related]
19. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713 [TBL] [Abstract][Full Text] [Related]
20. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]